Home › Free Stock Grades › SRPT
Sarepta Therapeutics, Inc. (SRPT) Stock Grade
SRPT · Healthcare
B-
Market Cap
$2.0B
P/E Ratio
—
Revenue Growth (YoY)
+15.6%
Net Margin
-32.5%
Return on Equity
—
Dividend Yield
None
About Sarepta Therapeutics, Inc.'s fundamentals
Sarepta Therapeutics is a $2.0 billion biotechnology company with revenue growth of 15.6% year-over-year, indicating expanding commercial sales. However, the company operates at a significant loss, with a net margin of -32.5% on its latest annual statement, reflecting the high costs typical of early-stage biotech firms developing specialized therapies. The company does not currently pay a dividend, and its traditional profitability metrics are not applicable due to its loss-making status.